Beijing Konruns Pharmaceutical Co.,Ltd. (SHA:603590)
China · Delayed Price · Currency is CNY 42.93
+0.38 (0.89%)
Jan 23, 2026, 3:00 PM CST
Beijing Konruns Pharmaceutical Company Description
Beijing Konruns Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of pharmaceuticals in China and internationally.
The company offers agkistrodon acutus hemocoagulase under Suling trade name, a single-component hemocoagulase clinical hemostatic drug for surgical operations.
It is also involved in the development of drug candidates, including ZY5301 that is in phase 3 clinical trials for the treatment of chronic pelvic pain in sequelae of pelvic inflammatory disease; and KC1036, which is in phase 2 clinical trial for the treatment of solid tumors.
The company was founded in 2003 and is headquartered in Beijing, China.
Beijing Konruns Pharmaceutical Co.,Ltd.
| Country | China |
| Founded | 2003 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 668 |
| CEO | Zhanqi Niu |
Contact Details
Address: Building 3, No. 7 Science Park Road Beijing, 102206 China | |
| Phone | 86 10 8289 8898 |
| Website | konruns.cn |
Stock Details
| Ticker Symbol | 603590 |
| Exchange | Shanghai Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| ISIN Number | CNE1000036K3 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Zhanqi Niu | President and Director |
| Xiaohan Liu | Chief Financial Officer and Director |
| Jing Wang | Accounting Supervisor |
| Xiao Dong Huang | Secretary to the Board |